OCRX Ocera Therapeutics, Inc.

1.25
+0  (4%)
Previous Close 1.20
Open 1.16
Price To book 1.80
Market Cap 29.50M
Shares 23,600,000
Volume 1,056,030
Short Ratio 0.35
Av. Daily Volume 3,086,740

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released January 30, 2017 - primary endpoint not met. Plans to meet with FDA 3Q 2017 - noted March 8, 2017.
OCR-002 (IV)
Hepatic encephalopathy
Phase 2a trial to be initiated 1H 2017.
OCR-002
Cirrhosis

Latest News

  1. Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  2. OCERA THERAPEUTICS, INC. Financials
  3. Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  4. OCERA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
  5. Ocera Therapeutics, Inc.: Yet Another Step Towards Putting a New Drug Treatment for Chronic Orphan Liver Diseases
  6. Here’s What’s Moving Immunomedics, Inc. (IMMU) And Ocera Therapeutics Inc (OCRX)
  7. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  8. Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  9. Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Ocera Therapeutics and Array Biopharma
  10. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
  11. Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
  12. Five Penny Stocks to Buy Now
  13. Ocera to Present at the Cowen and Company 37th Annual Healthcare Conference
  14. Lifshitz & Miller LLP Announces Investigation of Centrue Financial Corporation, Motorola Solutions, Inc., Natus Medical Incorporated, Northern Dynasty Minerals Ltd., Ocera Therapeutics, Inc., Psychemedics Corporation, RH and Stemline Therap
  15. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocera Therapeutics, Inc.
  16. Ocera Therapeutics downgraded by JMP Securities
  17. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  18. Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy
  19. ETFs with exposure to Ocera Therapeutics, Inc. : January 19, 2017
  20. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events